Epidarex Capital backs Enterprise Therapeutics
UK-based Enterprise Therapeutics Ltd, a drug discovery company focused on respiratory diseases, has received $2.4 million in Series A funding. The investor was Epidarex Capital.
17 February 2015•3 mins read
